Eliquis Tablet, Film Coated
Product Images NDC 50090-1436

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Eliquis (NDC 50090-1436). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Apixaban Chemical Structure (Apixaban Struct)

FDA Label Image

Aristotle Forest Plot (Eliquis Clin Forest Fig5)

FDA Label Image

Aristotle Major Bleeding Forest Plot (Eliquis Forest Fig1)

Aristotle Major Bleeding Forest Plot (Eliquis Forest Fig1)
This is a table with different subgroups of patients comparing the use of Apixaban versus Warfarin in terms of event occurrence. The table shows the number of patients, the percentage per year, the hazard ratio, and the corresponding confidence interval for each subgroup. The subgroups are classified by patient characteristics such as age, weight, stroke or TIA history, and geographic region. The table also shows whether randomization was used and if the patient has diabetes or a certain score on the CHADS scale. The table indicates that Apixaban has better results in terms of event occurrence compared to Warfarin in various subgroups of patients.*
FDA Label Image

Aristotle Kaplan-meier Curve (Eliquis Km Fig4)

FDA Label Image

Effects Of Drugs On Pk (Eliquis Pkplot Drugs Fig2)

Effects Of Drugs On Pk (Eliquis Pkplot Drugs Fig2)
This appears to be a table or chart showing the interaction of certain drugs with P-gp and CYP3A4 inhibitors and inducers. The table shows the fold change in drug PK (pharmacokinetics) and 90% CI (confidence interval) for drugs such as ketoconazole, glarithromycin, diltiazem, naproxen, and rifampin. The table also shows the AUC (area under the curve) and the relative change in comparison to a reference drug.*
FDA Label Image

O:\e-submissions\pbo\products\eliquis 202155\08. Pas Esrd Dosing\01. Orig Submission\source\eliquis-pkplot-pop-fig3.jpg (Eliquis Pkplot Pop Fig3)

O:\e-submissions\pbo\products\eliquis 202155\08. Pas Esrd Dosing\01. Orig Submission\source\eliquis-pkplot-pop-fig3.jpg (Eliquis Pkplot Pop Fig3)
This is a population description for PK parameters for various renal and hepatic impairments, age groups, and body weights. The data shows fold change and 90% CI for different parameters relative to the reference, and provides dosing recommendations, including "no dose adjustment" and "dosing recommendation cannot be provided".*
FDA Label Image

Label Image (Lbl500901436)

Label Image (Lbl500901436)
This text appears to be a label for a medication named "APTXABAN" which contains 2.5 MG and has 60 tablets. The label also provides storage instructions to keep the medication at 6870 7 degrees Celsius. The other text "1mc, zes, préduct. 6813-0, tllous" is not clear and cannot be understood.*
FDA Label Image

Label Image (Lbl500901437)

Label Image (Lbl500901437)
This appears to be a label for a medication called "APTXABAN" with a strength of 5mg. The label indicates that the medication should be stored at 68-77 degrees Fahrenheit and includes 60 tablets. No further information is available.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.